A retrospective, multicenter study assessing the efficacy and safety ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer
Latest Information Update: 14 Feb 2023
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 11 Feb 2023 Results assessing sequencing strategies of ramucirumab and docetaxel following prior treatments, including immune checkpoint inhibitor (ICI), cytotoxic agent alone, bevacizumab, and tyrosine kinase inhibitor (TKI), published in the European Journal of Clinical Pharmacology.
- 20 Jan 2022 New trial record
- 13 Jan 2022 Primary endpoint (progression-free survival) not met according to the results published in the investigational new drugs